Eyegate Pharmaceuticals (NASDAQ:EYEG) is set to release its earnings data on Wednesday, February 21st. Analysts expect Eyegate Pharmaceuticals to post earnings of ($0.24) per share for the quarter.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last issued its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.24). Eyegate Pharmaceuticals had a negative net margin of 2,480.28% and a negative return on equity of 1,494.75%. On average, analysts expect Eyegate Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eyegate Pharmaceuticals (EYEG) opened at $0.68 on Wednesday. Eyegate Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market cap of $11.53 and a PE ratio of -0.58.
A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. grew its holdings in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the quarter. Vanguard Group Inc. owned approximately 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.94% of the company’s stock.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.